We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Foul API Batches and Data Integrity Issues Result in FDA Warning for Cadila
Foul API Batches and Data Integrity Issues Result in FDA Warning for Cadila
The FDA has cited Cadila Pharmaceuticals for poor data integrity practices and sloppy investigations into foul smelling batches of active pharmaceutical ingredients (APIs), violations that the agency threatened could result in an import alert.